Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia
Open Access
- 1 March 2009
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 199 (5) , 619-624
- https://doi.org/10.1086/596629
Abstract
Background Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infections are emerging, but their clinical significance remains unclear. Our objective was to compare patients who had hVISA bacteremia with patients who had methicillin-resistant S. aureus (MRSA) bacteremia Methods A total of 27 case patients with hVISA bacteremia were compared with 223 control patients with MRSA bacteremia. Medical records of all patients were reviewed, and factors independently associated with infection-related mortality were assessed by logistic regression Results Patients with hVISA bacteremia were not significantly different from those with MRSA bacteremia with respect to age, comorbidities, duration of hospital stay, and infection-attributable mortality. However, the median duration of bacteremia among patients with hVISA was significantly longer than that among patients with MRSA (12 vs. 2 days; P=.005), and patients with hVISA had a greater prevalence of complications, such as endocarditis (18.5% vs. 3.6%; P=.007) and osteomyelitis (25.9% vs. 7.2%, respectively; P=.006). Rifampin resistance emerged more frequently among hVISA isolates than among MRSA isolates (44% vs. 5.9%; P<.001). Factors independently associated with infection-related mortality in all patients were age, Charlson comorbidity index, female sex, and being bedridden Conclusions hVISA bacteremia was significantly associated with prolonged bacteremia duration, greater rates of complications, and emergence of rifampin resistance, compared with MRSA bacteremia. However, no significant difference in mortality existed between patients with hVISA bacteremia and those with MRSA bacteremiaKeywords
This publication has 21 references indexed in Scilit:
- Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care CenterJournal of Clinical Microbiology, 2007
- Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United StatesAnnals of Clinical Microbiology and Antimicrobials, 2006
- The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureusClinical Microbiology & Infection, 2006
- A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospitalJournal of Antimicrobial Chemotherapy, 2005
- Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic MethodsAntimicrobial Agents and Chemotherapy, 2003
- Infection with Vancomycin-ResistantStaphylococcus aureusContaining thevanAResistance GeneNew England Journal of Medicine, 2003
- The Prevalence and Mechanisms of Vancomycin Resistance in Staphylococcus AureusAnnual Review of Microbiology, 2002
- Survey of Infections Due toStaphylococcusSpecies: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997–1999Clinical Infectious Diseases, 2001
- Vancomycin-Intermediate and -Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to KnowClinical Infectious Diseases, 2001
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997